Investigation of safety, tolerability and immunogenicity of a candidate vaccine, including evaluation of both humoral and cellular responses. This is the first study of the two component HIV DNA vaccine (APL 400-003 & 400-047) administered to HIV infected volunteers to evaluate safety, tolerance and immune response. Results of this study will be used to guide future ones.
Showing the most recent 10 out of 423 publications